.After a handful of years in biotech, Mike Quigley, Ph.D., is actually going back to the pharma layer, taking up the leading science area at Sanofi.Quigley is going to start Sept. 30 as the French Big Pharma's chief medical police officer and also global head of research, Sanofi informed Fierce Biotech in an emailed statement.Quigley is actually replacing Frank Nestle, M.D., who left behind Sanofi this spring season in the middle of an international overhaul of the provider's R&D unit. Nestle, that spent eight years with the pharma, hopped over to Deerfield Control, where he presently works as a companion on the therapeutics staff as well as chief executive officer of the company's healing discovery as well as advancement procedures.
Quigley is going to join Sanofi coming from a San Francisco-based biotech that remains in stealth, according to his LinkedIn profile page. He's currently provided as the firm's co-founder, head of state and chief executive officer.Since August 2021, Quigley has actually worked as an endeavor companion at SV Health and wellness Investors, a healthcare fund manager along with current investments in biotechs like BioAge, Cerevance, Dualitas Therapies as well as Nimbus Rehabs, among others. Quigley in the past stored the top place at Dualitas, a biotech that continues to be in secrecy, according to STAT.The prospective Sanofi innovator additionally formerly helmed Therini Biography, an immunotherapy biotech operating to develop therapies for neurodegenerative health conditions driven through vascular disorder.Prior to devoting the last couple of years in biotech, Quigley possesses an also longer performance history in Major Pharma, very most just recently working as Gilead's elderly bad habit president of study biology until the summertime of 2021. Just before that, he clocked in more than 4 years around numerous leadership tasks at Bristol Myers Squibb and also functioned as a clinical director at Johnson & Johnson's Janssen arm just before that.Sanofi stated Quigley's purpose in his brand-new part would be to "optimize our probability of results through ideal partnerships all over our company and also beyond, bringing best-in-class technology in addition to creating and also sourcing brand-new industry-leading ability with a commitment to variety," according to an internal memo secured by STAT.